Danazol for the treatment of idiopathic thrombocytopenic purpura.
Fourteen patients with idiopathic thrombocytopenic purpura (ITP) refractory to steroids and/or splenectomy were treated with danazol (200 mg 3 times a day) for 2 months. The following responses were achieved: excellent (platelet count greater than 100 X 10(9)/l) in 5 patients; good (greater than 50 X 10(9)/l, but less than 100 X 10(9)/l) in 2 patients, and poor in (no increase of platelet count) 7 patients. In three cases remission lasted more than 7 months. Danazol was well tolerated and in most patients better suited than steroids for long-term intake.
D000328:Adult; D000368:Aged; D003613:Danazol / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011245:Pregnadienes / Q000627:therapeutic use*; D011696:Purpura, Thrombocytopenic / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D013156:Splenectomy
D005938:Glucocorticoids; D011245:Pregnadienes; D003613:Danazol